共 351 条
[1]
Chester W(1930)Über Lipoidgranulomatose Virchows Arch Pathol Anat 279 561-602
[2]
Haroche J(2012)High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses Blood. 120 2700-2703
[3]
Charlotte F(2016)Diverse and targetable kinase alterations drive histiocytic neoplasms Cancer Discov 6 154-165
[4]
Arnaud L(2014)Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease Blood. 124 3016-3019
[5]
von Deimling A(2013)Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation Blood. 121 1495-1500
[6]
Hélias-Rodzewicz Z(2015)Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease J Clin Oncol 33 411-418
[7]
Hervier B(2017)Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study) Blood. 130 1377-1380
[8]
Diamond EL(2019)Efficacy of MEK inhibition in patients with histiocytic neoplasms Nature. 567 521-524
[9]
Durham BH(2016)Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages Blood. 127 2672-2681
[10]
Haroche J(2002)Mutations of the BRAF gene in human cancer Nature. 417 949-954